What this Trial Is About

Researchers are evaluating the impact of a new multi-infusion strategy on the rate of central line-associated bloodstream infections (CLABSI) in very preterm infants hospitalized in neonatal units. The study focuses on infants born at or before 32 weeks gestation and weighing 1600 grams or less. The purpose is to see if this strategy can reduce infections, antibiotic use, catheter problems, and stressful procedures compared to usual care. This approach builds upon a pilot study at Croix-Rousse hospital that showed promising reductions in infection rates using the EDELVAISS multi-infusion devices. The study compares two approaches: the routine reference strategy using usual catheters and infusion systems, and the experimental EDELVAISS multi-infusion strategy. This new method uses specialized devices designed for neonatal care to deliver multiple intravenous drugs and nutrition solutions safely and efficiently. The strategy aims to lower infection risks and improve care by minimizing line manipulations and device-related complications. Participants are very preterm infants admitted within the first three days of life who need infusion sets for multiple drugs or solutions. They will be monitored during their hospital stay, with researchers tracking infection rates up to six months. Data collection includes recording catheter-related bloodstream infections and observing catheter performance and complications. The study also involves parental consent and excludes infants with certain severe conditions or participation in conflicting studies. The total participation period depends on the infant's hospital stay and clinical course.

Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections